At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 136 enrolled
Drug / intervention
Povorcitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria
In Brief
A Phase 2 clinical trial evaluating Povorcitinib and Placebo for Urticaria and 5 related conditions. Completed, enrolled 136 participants across 42 sites in 3 countries.
Detailed Summary
This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
CountriesGermany, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
First PostedJul 2023
Enrollment StartJul 2023
Primary CompletionFeb 2025
Study CompletionOct 2025
TodayJul 2026
First PostedJul 7, 2023
Enrollment StartJul 31, 2023
Primary CompletionFeb 28, 2025
Study CompletionOct 9, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.0 years ago
Interventions
Povorcitinibdrug
oral; tablet
Placebodrug
oral; tablet